Urinary excretion of angiogenesis regulatory factors and renal injury markers in chronic glomerulonephritis: Significance in the assessment of progression

Full Text

Abstract

Aim. To study the urinary excretion of the molecular factors regulating angiogenesis, such as vascular endothelial growth factor type A (VEGF-A), thrombospondin 1 (THBS1), and angiopoietin 2 (ANGPT2), versus that of the urinary markers of renal injury and fibrogenesis, such as neutrophil gelatinase-associated lipocalin (NGAL), type IV collagen (COL4), and known clinical risk factors for accelerated disease progression to estimate the prognostic value of urinary excretion in patients with chronic glomerulonephritis (CGN). Subjects and methods. Eighty-two patients (45% men, 55% women; mean age, 36.5 years) with a clinical diagnosis of CGN were examined. 31.7% of the examinees presented with nephrotic syndrome; 31.7% had a glomerular filtration rate (GFR) of less than 60 ml/min/1.73 m2. Morning urine samples were analyzed by Elisa to determine the urinary excretion of biomarkers (VEGF-A, THBS1, ANGPT2, NGAL, and COL4). The results were adjusted to urinary creatinine concentrations. Results. The urinary excretion of the angiogenesis regulators VEGF-A, THBS1, and ANGPT2 correlated between them, with that of the renal injury markers NGAL and COL4, with the level of proteinuria. That was found to be unassociated with blood pressure and GFR. In the presence and absence of nephrotic syndrome, high (>75th percentile) urinary excretion rates were 46.2 and 14.8% for VEGF-A (р<0.01); 50 and 13% for THBS1 (р<0.001); and 46.2 and 14.8% for ANGPT2 (р<0.01), respectively. That for ANGPT2 was also high in the presence of anemia (63.2 versus 11.7%; p<0.001). Conclusion. The finding of the high urinary excretion of the angiogenesis regulators VEGF-A, THBS1, and ANGPT2 and its association with that of kidney injury markers in the patients with the proteinuric forms of CGN suggest that this excretion may be considered as an integral index that displays glomerular injury and indicates tubulointerstitial proteinuric/hypoxic remodeling.

References

  1. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Под ред. Смирнова А.В. Нефрология. 2012;16(1):15-89.
  2. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258-1270. doi: 10.1038/ki.2011.368.
  3. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper M, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80(8):806-821. doi: 10.1038/ki.2011.198.
  4. Fine L, Ong A, Norman J. Mechanisms of tubulointerstitial injury in progressive renal diseases. Eur J Clin Invest. 1993;23(5):259-265.
  5. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17-25.
  6. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. KidneyInt. 2008;74(7):867-872. doi: 10.1038/ki.2008.350.
  7. Tanaka T, Nangaku M. Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol. 2013;9(4):211-222. doi: 10.1038/nrneph.2013.35.
  8. Kang DH, Joly H, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001;12(7):1434-1447.
  9. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol. 2001;12(7): 1448-1457.
  10. Козловская Л.В., Варшавский В.А., Бобкова И.Н., Голицына Е.П., Рамеева А.С. Клиническое значение определения в моче маркеров эндотелиальной дисфункции и факторов ангиогенеза в оценке тубулоинтерстициального фиброза при хроническом гломерулонефрите. Терапевтический архив. 2007;6:10-15.
  11. Чеботарева Н.В., Бобкова И.Н., Козловская Л.В. Нефринурия как показатель структурно-функциональных нарушений гломерулярного фильтра у больных протеинурическими формами нефрита. Клиническаянефрология. 2010;4:45-51.
  12. Чжэн А., Швецов М.Ю., Бобкова И.Н., Ли О.А. Уровень сосудистого эндотелиального фактора роста а типа (VEGF A) и карбоангидразы ix (CA 9) мочи у больных хроническим гломерулонефритом: связь с клинической активностью заболевания и нарушением функции почек. Сборник тезисов VII съезда Научного общества нефрологов России, 19—22 октября 2010 г. М.; 2010:136-137.
  13. Hoeben A, Landuyt B, Highley M. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549-580.
  14. Ferrara N. Vascular endothelial growth factor. Arterioscler ThrombVasc Biol. 2009;29(6):789-791.
  15. Парфенова Е.В., Ткачук В.А. Терапевтический ангиогенез: достижения, проблемы, перспективы. Кардиологический вестник. 2007;II(XIV)(2):5-14.
  16. Villegas G, Lange-Sperandio B, Tufro A. Autocrine and paracrine functions of vascular endothelial growth factor (VEGF) in renal tubular epithelial cells. Kidney Int. 2005;67(2):449-457.
  17. Hugo C, Daniel C. Thrombospondin in renal disease. Nephron Exp Nephrol. 2009;111(3):61-66.
  18. Bige N, Shweke N, Benhassine S, Jouanneau C, Vandermeersch S, Dussaule J-C, Chatziantoniou C, Ronco P, Boffa JJ. Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. Kidney Int. 2012;81(12):1226-1238. doi: 10.1038/ki.2012.21.
  19. Hugo C. The thrombospondin 1-TGF-axis in fibrotic renal disease. Nephrol Dial Transplant. 2003;18(7):1241-1245.
  20. Woolf AS, Gnudi L, Long D. Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol. 2009;20(2):239-244. doi: 10.1681/asn.2008020243.
  21. Pichiule P, Chavez JC, LaManna JC. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem. 2004;279(13):12171-12180.
  22. Швецов М.Ю., Иванов А.А., Кузнецова А.В., Попова О.П., Рамеева А.С. Молекулярные факторы ангиогенеза в ткани почки больных хроническим гломерулонефритом: связь с нефросклерозом и анемией. Терапевтический архив. 2009;8:14-20.
  23. Швецов М.Ю., Попова О.П., Кузнецова А.В., Иванов А.А., Маунг Маунг М. Фактор, индуцируемый гипоксией, 1 типа (HIF-1) как маркер хронической ишемии почечного тубулоинтерстиция у больных хроническим гломерулонефритом: связь с клинической активностью заболевания и облитерацией перитубулярного капиллярного русла. Сборник тезисов VII съезда Научного общества нефрологов России, 19—22 октября 2010 г. М.; 2010:144-146.
  24. Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, Shen W, Kopp JB, Thomas DB, Tufro A. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int. 2010;77(11):989-999. doi: 10.1038/ki.2010.64.
  25. Villanueva S, Céspedes C, Vio CP. Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol. 2006;290(4):R861-870.
  26. Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol. 2007;3(5):287-293.
  27. Cina DP, Xu H, Liu L, Farkas L, Farkas D, Kolb M, Margetts PJ. Renal tubular angiogenic dysregulation in anti-Thy1.1 glomerulonephritis. Am JPhysiol Renal Physiol. 2011;300(2):F488-F498. doi: 10.1152/ajprenal.00214.2010.
  28. Shvetsov M, Ivanov A, Uribe Villegas V, Popova O. Morphologic markers of intrarenal blood flow and angiogenesis disorders in chronic glomerulonephritis: association with systemic hypertension and disease activity. Abstracts of 49th European Renal Association European Dialysis and Transplantation Association (ERA-EDTA) Congress, 2012, Paris 2012:SAP427.
  29. Goligorsky MS. Microvascular rarefaction: the decline and fall of blood vessels. Organogenesis. 2010;6(1):1-10.
  30. Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Böttinger EP, Chen Y, Zhu HJ, Kang DH, Schreiner GF, Lan HY, Johnson RJ. TGF-beta induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways. Kidney Int. 2004;66(2):605-613.
  31. Nangaku M, Eckardt K. Hypoxia and the HIF system in kidney disease. J Mol Med. 2007;85(12):1325-1330.
  32. Stockmann C, Fandrey J. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp PharmacolPhysiol. 2006;33(10):968-979.

Statistics

Views

Abstract: 145

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2015 Shvetsov M.Y., Zheng A., Kozlovskaya L.V., Serova A.G., Travkina E.V., Mukhin N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies